Thrombolysis in acute ischaemic stroke

Journal of Clinical Neuroscience

Volumn 8, Issue 2, 2001, Pages 112-115

  Donnan, Geoffrey A ^a   Davis, Stephen M ^b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANCROD; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DISABILITY; HEMATOMA; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0035088008     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2000.0813     Document Type: Review

References (24)

1. Do stroke units save lives?
2. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
3. CAST: Randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke
4. The ischemic penumbra
5. Tissue plasminogen activator reduces neurological damage after cerebral embolism
6. A pilot study of urokinase therapy in cerebral infarction
7. Clinical effect of urokinase (60 000 units/day) on cerebral infarction-comparative study by means of multiple center double blind test
8. Therapeutic thrombolysis in cerebral thromboembolism: Randomised evaluation of intravenous streptokinase
9. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
10. Thrombolytic therapy with streptokinase in acute ischemic stroke
11. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
12. Tissue plasminogen activator for acute ischemic stroke
13. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
14. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
15. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial
16. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: A randomized controlled trial
17. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings
18. Acute stroke: Usefulness of early CT findings before thrombolytic therapy
19. Local intra-arterial fibrinolytic therapy in patients with stroke: Urokinase versus recombinant tissue plasminogen activator (r-TPA)
20. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease
21. Intra-arterial streptokinase in acute ischaemic stroke. A pilot study
22. Defibrinogenation with Viprinex (ANCROD) for the treatment of acute ischemic stroke
23. Limiting neurological damage after stroke: A review of pharmacological treatment options
24. Does neuroprotection improve stroke outcome?